Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market engagement, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service aims to help investors become more informed and confident in their investment decisions [1] Group 2: Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2] - Stocks are rated from A to F, with A indicating the highest potential for outperforming the market [3] Group 3: Value Score - The Value Style Score focuses on identifying undervalued stocks by analyzing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Group 4: Growth Score - The Growth Style Score assesses a company's financial health and future outlook by examining projected and historical earnings, sales, and cash flow [4] Group 5: Momentum Score - The Momentum Style Score identifies optimal times to invest based on price trends and earnings estimate changes, emphasizing the importance of market trends [5] Group 6: VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive rating to identify stocks with the best overall potential [6] Group 7: Zacks Rank and Style Scores Integration - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988 [7] - The integration of Style Scores with the Zacks Rank helps investors narrow down their choices among over 800 top-rated stocks [8] Group 8: Stock Example - Conmed Corporation - Conmed Corporation, a medical products manufacturer, is currently rated 3 (Hold) on the Zacks Rank with a VGM Score of A [11] - The company has a Momentum Style Score of B, with shares increasing by 8.6% over the past four weeks, and has seen upward revisions in earnings estimates for fiscal 2025 [12]

Group 1 - Zacks Premium offers tools for investors to enhance their stock market confidence and knowledge, including daily updates, research reports, and stock screens [1][2] - The Zacks Style Scores provide ratings based on value, growth, and momentum characteristics, helping investors identify stocks with high potential to outperform the market [2][3] Group 2 - The Value Score identifies attractive and discounted stocks using various financial ratios, appealing to value investors [3] - The Growth Score focuses on a company's future prospects and financial health, analyzing earnings, sales, and cash flow [4] - The Momentum Score helps investors capitalize on price trends by analyzing recent price changes and earnings estimate shifts [5] Group 3 - The VGM Score combines the three Style Scores to identify stocks with the best value, growth, and momentum characteristics, serving as a strong indicator alongside the Zacks Rank [6] - The Zacks Rank model, based on earnings estimate revisions, has shown a historical average annual return of +23.75% for 1 (Strong Buy) stocks since 1988, significantly outperforming the S&P 500 [7][9] Group 4 - CONMED Corporation, a medical products manufacturer, is currently rated 3 (Hold) on the Zacks Rank with a VGM Score of A, indicating potential for investors [11] - The company has a Momentum Style Score of A, with shares increasing by 4.8% over the past four weeks, and an upward revision in earnings estimates for fiscal 2025 [12]

Company Overview - CONMED Corporation is a major medical products manufacturer specializing in surgical instruments and devices for minimally invasive procedures and monitoring [12] - The company is headquartered in Utica, N.Y., employs approximately 3,600 individuals, and operates several manufacturing facilities [12] Investment Ratings - CONMED has a Zacks Rank of 3 (Hold) with a VGM Score of B, indicating a moderate investment outlook [12] - The company also has a Value Style Score of A, attributed to attractive valuation metrics such as a forward P/E ratio of 12.88, which may appeal to value investors [13] Earnings Estimates - For fiscal 2025, three analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.07 to $4.42 per share [13] - CONMED has demonstrated an average earnings surprise of 10.4%, suggesting a positive trend in earnings performance [13] Investment Considerations - With a solid Zacks Rank and top-tier Value and VGM Style Scores, CONMED is recommended for investors' consideration [13]